In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin.
Fosmidomycin acts through inhibition of 1-deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase, a key enzyme of the nonmevalonate pathway of isoprenoid biosynthesis. It possesses potent antimalarial activity in vitro and in murine malaria. In a recent clinical study, fosmidomycin was effective and well tolerated in the treatment of patients with acute uncomplicated Plasmodium falciparum malaria but resulted in an unacceptably high rate of recrudescence. In order to identify a potential combination partner, the interaction of fosmidomycin with a number of antimalarial drugs in current use was investigated in a series of in vitro experiments. Synergy was observed between fosmidomycin and the lincosamides, lincomycin and clindamycin. The efficacy of a combination of fosmidomycin and clindamycin was subsequently demonstrated in the Plasmodium vinckei mouse model.
Institute of Biochemistry, Academic Hospital Centre, Justus-Liebig-University, Giessen, Germany. Jochen.Wiesner@Jomaa.de
Jochen
J
Wiesner
Dajana
D
Henschker
David B
DB
Hutchinson
Ewald
E
Beck
Hassan
H
Jomaa
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000962:Antimalarials / Q000494:pharmacology*; D002981:Clindamycin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005578:Fosfomycin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D006801:Humans; D008288:Malaria / Q000188:drug therapy / Q000469:parasitology; D051379:Mice; D010963:Plasmodium falciparum / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D000962:Antimalarials; D005578:Fosfomycin; D002981:Clindamycin; C024640:fosmidomycin